Press Releases

Date Title and Summary View
Toggle Summary ZOSANO PHARMA, INC. ANNOUNCES ZOSANO PHARMA, INC. COMPLETES POSITIVE END-OF-PHASE 2 MEETING WITH FDA REGARDING ZP- PTH PATCH FOR OSTEOPOROSIS
ZOSANO PHARMA, INC. ANNOUNCES ZOSANO PHARMA, INC. COMPLETES POSITIVE END-OF-PHASE 2 MEETING WITH FDA REGARDING ZP- PTH PATCH FOR OSTEOPOROSIS Fremont, Calif. – December 9, 2008 – Zosano Pharma, Inc., a privately held pharmaceutical company developing products using a novel transdermal
View HTML
Toggle Summary Zosano Pharma, Inc. Completes Positive End-Of-Phase 2 Meeting With Fda Regarding ZP- PTH Patch.
Zosano Pharma, Inc. Completes Positive End-Of-Phase 2 Meeting With Fda Regarding ZP- PTH Patch. Fremont, Calif. – December 9, 2008 – Zosano Pharma, Inc., a privately held pharmaceutical company developing products using a novel transdermal delivery technology, today announced that it
View HTML
Toggle Summary ZOSANO PHARMA, INC. ANNOUNCES POSITIVE RESULTS OF PHASE 2 OSTEOPOROSIS STUDY
ZP-PTH Patch Demonstrates Increase in Lumbar Spine and Hip Bone Mineral Density
View HTML
Toggle Summary ZOSANO PHARMA, INC. TO PRESENT AT BIO INVESTOR FORUM
ZOSANO PHARMA, INC. TO PRESENT AT BIO INVESTOR FORUM Fremont, Calif. – October 23, 2008 – Zosano Pharma, Inc., a privately held pharmaceutical company developing a novel transdermal delivery technology for a broad range of therapeutic indications, announced today that John Vuko, Chief
View HTML
Toggle Summary ZOSANO PHARMA, INC. ANNOUNCES POSITIVE RESULTS OF PHASE 2 TRIAL WITH PTH TRANSDERMAL PATCH IN OSTEOPOROSIS
DATA TO BE PRESENTED AT ACR SCIENTIFIC MEETING
View HTML
Toggle Summary ZOSANO PHARMA, INC. ANNOUNCES APPOINTMENT OF GAIL SCHULZE AS CHAIR AND CEO
New Senior Management Appointments Strengthen Executive Team
View HTML
Toggle Summary Zosano Pharma, Inc. Closes Enrollment in Phase 2 Trial
Company Continues Implementation Focus on Trial Milestones and Partnership Opportunities
View HTML
Toggle Summary Zosano Pharma, Inc. Announces Funding Close Totaling $90 Million
Zosano Pharma, Inc. Announces Funding Close Totaling $90 Million FREMONT, Calif.--(BUSINESS WIRE)--Zosano Pharma, Inc., an emerging specialty pharmaceutical company focused on developing better pharmaceutical products using innovative drug delivery, has announced the receipt of the second half of
View HTML
Toggle Summary Macroflux Announces Name Change to Zosano Pharma, Inc.
Macroflux Announces Name Change to Zosano Pharma, Inc. FREMONT, Calif.--(BUSINESS WIRE)--Sept. 27, 2007--The Macroflux Corporation announced today that it has changed the name of the company to Zosano Pharma, Inc. "Our name change reflects the positive evolutionary steps the company is taking to
View HTML
Toggle Summary Macroflux Names M. Cory Zwerling President, CEO
Macroflux Names M. Cory Zwerling President, CEO Macroflux, an emerging specialty pharmaceutical company focused on the development of proprietary products, has named M. Cory Zwerling President and CEO of the company. “This is an exciting opportunity to lead Macroflux with a strong team,
View HTML